Replimune Positive Topline Primary Analysis Data in Melanoma Trial

 Primary endpoint data shows 12-month overall response rate (ORR) of 33.6%

Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024

Company to host conference call and webcast today at 8:00 a.m. ET

Replimune will host a conference call and webcast today at 8:00 a.m. ET. Listeners can register for the conference call via this link. Analysts wishing to participate in the question-and-answer session should use this link. The webcast and slides of the presentation can be accessed in the Investors section of the Company’s website at www.replimune.com. A replay of the webcast will be available on the Company’s investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

https://www.biospace.com/article/releases/replimune-announces-positive-topline-primary-analysis-data-by-independent-central-review-from-ignyte-clinical-trial-of-rp1-plus-nivolumab-in-anti-pd1-failed-melanoma/